Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Registration Number
- NCT05503550
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of talquetamab in targeting GPRC5D for relapsed or refractory multiple myeloma treatment?
How does talquetamab compare to standard-of-care therapies like daratumumab in treating relapsed/refractory multiple myeloma?
Which biomarkers correlate with talquetamab response in patients with relapsed or refractory multiple myeloma?
What adverse events are associated with talquetamab monotherapy in multiple myeloma clinical trials?
Are there combination therapies involving talquetamab and other Janssen investigational agents for multiple myeloma?